Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
Brandon Michael Henry, Chief Executive and Medical Officer at Aurelix Bio, shared a post on Linkedin about a recent article he and his colleague co-authored, published in Seminars in Thrombosis and Hemostasis, adding:
“Complement activation after AAV gene therapy is complex to interpret.
Early post-dose changes in platelets, C3/C4, or soluble C5b-9 do not automatically mean toxicity. In many cases, they may reflect expected pharmacodynamic engagement of innate immunity after vector exposure.
The clinical challenge is recognizing when that biology remains self-limited – and when it begins to evolve toward sustained complement amplification, endothelial injury, and thrombotic microangiopathy.
Our article in Seminars in Thrombosis and Hemostasis focuses on that interpretive boundary.
We provide a practical framework for integrating complement biomarkers with hematologic and renal markers, with emphasis on assay limitations, timing, trajectory, and clinical context.
The main point: gene therapy safety monitoring should not only ask whether complement activation is present.
It should ask what pattern it is following, whether it is resolving or escalating, and whether the broader clinical picture suggests expected biology or early vascular injury.”
Title: Laboratory Monitoring of Complement Activation in Gene Therapy: Analytical Pitfalls and Clinical Interpretation
Authors: Brandon M Henry, Melvin Y Rincon, Giuseppe Lippi, Zoltán Prohászka, Stefanie Benoit
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering